ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
Globenewswireยท2025-10-28 12:00
To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, is pleased to announce the strategic collaboration with Dr. Iman Barilero, PharmD, PhD, as Senior Advisor for Regulatory Affairs to suppo ...